Evidence map›Paper›PMID 24837480›Full record

ArticleGastroenterology2014

Activation of β-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice.

Junyan Tao, Diego F Calvisi, Sarangarajan Ranganathan, Antonio Cigliano, Lili Zhou, Sucha Singh, Lijie Jiang, Biao Fan, Luigi Terracciano, Sorin Armeanu-Ebinger and 5 more

Open access · bronzeAbstract readComparative StudyMulticenter Study
In one paragraph

Article in Gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 191 papers.

0numbers the graph read from it
0cells of the map it votes in
191citing papers in PubMed
9.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

191 citing papers in PubMed, 340 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Trefoil Factor-3 Is a Hypoxia-Triggered Pro-Tumorigenic Factor in Hepatoblastoma.Liver international : official journal of the International Association for the Study of the Liver · 2026
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Hepatoblastoma.Nature reviews. Disease primers · 2025
    Review

131 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 4 countries.

Junyan Tao *Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA.
Diego F Calvisi *Institute of Pathology, University of Greifswald, Greifswald, Germany.
Sarangarajan Ranganathan *Department of Pathology, University of Pittsburgh, School of Medicine, Pittsburgh, PA.
Antonio CiglianoInstitute of Pathology, University of Greifswald, Greifswald, Germany.
Lili ZhouDepartment of Pathology, University of Pittsburgh, School of Medicine, Pittsburgh, PA.
Sucha SinghDepartment of Pathology, University of Pittsburgh, School of Medicine, Pittsburgh, PA.
Lijie JiangDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA.
Biao FanDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA.
Luigi TerraccianoInstitute of Pathology, University Hospital Basel, Basel, Switzerland.
Sorin Armeanu-EbingerDepartment of Pediatric Surgery and Pediatric Urology, Children's University Hospital Tuebingen, Tuebingen, Germany.
Silvia RibbackInstitute of Pathology, University of Greifswald, Greifswald, Germany.
Frank DombrowskiInstitute of Pathology, University of Greifswald, Greifswald, Germany.
Matthias EvertInstitute of Pathology, University of Greifswald, Greifswald, Germany.
Xin ChenDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA.
Satdarshan P S MongaDepartment of Pathology, University of Pittsburgh, School of Medicine, Pittsburgh, PA.
Universität Greifswald · DEUniversity of California, San Francisco · USUniversity of Pittsburgh · USSecond Affiliated Hospital of Xi'an Jiaotong University · CNUniversity Children's Hospital Tübingen · DEUniversity Hospital of Basel · CH

Funding

UCSF Liver Core CenterP30DK026743 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Holger Willenbring · 1986 to 2026
$30.7M
Role of Wnt/Beta-Catenin Signaling in Liver DevelopmentR01DK062277 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Satdarshan Singh Monga · 2004 to 2026
$9.0M
Molecular Genetics of Liver CancersR01CA136606 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHEN, XIN · 2009 to 2016
$2.6M
Targeting beta-catenin in liver pathology: Novel Interactions, Novel ParadigmsR01DK100287 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MONGA, SATDARSHAN SINGH · 2013 to 2016
$1.3M
NCI NIH HHS 1R01CA136606NCI NIH HHS R01 CA136606NIDDK NIH HHS 1R01DK100287NIDDK NIH HHS 1R01DK62277NIDDK NIH HHS P30 DK026743NIDDK NIH HHS R01 DK062277NIDDK NIH HHS R01 DK100287
6 · The paper itself

Abstract

BACKGROUND &

aimsAberrant activation of β-catenin and Yes-associated protein 1 (Yap1) signaling pathways have been associated with the development of multiple tumor types. Yap functions as a transcriptional coactivator by interacting with TEA domain DNA binding proteins. We investigated the interactions among these pathways during hepatic tumorigenesis.

methodsWe used immunohistochemical analysis to determine expression of β-catenin and Yap1 in liver cancer specimens collected from patients in Europe and the United States, consisting of 104 hepatocellular carcinoma, 62 intrahepatic cholangiocarcinoma, and 94 hepatoblastoma samples. We assessed β-catenin and Yap1 signaling and interactions in hepatoblastoma cell lines ((HuH6, HepG2, HepT1, HC-AFW1, HepG2, and HC-AFW1); proteins were knocked down with small interfering RNAs, and effects on proliferation and cell death were measured. Sleeping beauty-mediated hydrodynamic transfection was used to overexpress constitutively active forms of β-catenin (ΔN90/β-catenin) and Yap1 (YapS127A) in livers of mice; tissues were collected, and histological and immunohistochemical analyses were performed.

resultsWe observed nuclear localization of β-catenin and Yap1 in 79% of hepatoblastoma samples but not in most hepatocellular carcinoma or intrahepatic cholangiocarcinoma samples. Yap1 and β-catenin coprecipitated in hepatoblastoma but not hepatocellular carcinoma cells. Small interfering RNA-mediated knockdown of Yap1 or β-catenin in hepatoblastoma cells reduced proliferation in an additive manner. Knockdown of Yap1 reduced its ability to coactivate transcription with β-catenin; β-catenin inhibitors inactivated Yap1. Overexpression of constitutively active forms of Yap1 and β-catenin in mouse liver led to rapid tumorigenesis, with 100% mortality by 11 weeks. Tumor cells expressed both proteins, and human hepatoblastoma cells expressed common targets of their 2 signaling pathways. Yap1 binding of TEA domain factors was required for tumorigenesis in mice.

conclusionsβ-catenin and the transcriptional regulator Yap1 interact physically and are activated in most human hepatoblastoma tissues; overexpression of activated forms of these proteins in livers of mice leads to rapid tumor development. Further analysis of these mice will allow further studies of these pathways in hepatoblastoma pathogenesis and could lead to the identification of new therapeutic targets.

Indexed as

Adaptor Proteins, Signal TransducingAnimalsbeta CateninBile Duct NeoplasmsBile Ducts, IntrahepaticCarcinoma, HepatocellularCell DeathCell ProliferationCell Transformation, NeoplasticCholangiocarcinomaEuropeGene Expression Regulation, NeoplasticHepatoblastomaHep G2 CellsHumansLiver NeoplasmsAdaptor Proteins, Signal Transducingbeta CateninCTNNB1 protein, humanPhosphoproteinsTranscription FactorsYAP1 protein, humanYAP-Signaling ProteinsGene RegulationLiver CancerOncogeneTumor Formation

Identifiers

PMID24837480
PMCPMC4143445
OpenAlexW2055254495

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.